➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Baxter
McKinsey
Express Scripts
AstraZeneca

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022206


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 022206 describes RAPAFLO, which is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. Additional details are available on the RAPAFLO profile page.

The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the silodosin profile page.
Summary for 022206
Tradename:RAPAFLO
Applicant:Allergan
Ingredient:silodosin
Patents:0
Pharmacology for NDA: 022206
Mechanism of ActionAdrenergic alpha-Antagonists
Suppliers and Packaging for NDA: 022206
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RAPAFLO silodosin CAPSULE;ORAL 022206 NDA Allergan, Inc. 0023-6142 0023-6142-30 30 CAPSULE in 1 BOTTLE, UNIT-DOSE (0023-6142-30)
RAPAFLO silodosin CAPSULE;ORAL 022206 NDA Allergan, Inc. 0023-6142 0023-6142-90 90 CAPSULE in 1 BOTTLE, UNIT-DOSE (0023-6142-90)
Paragraph IV (Patent) Challenges for 022206
Tradename Dosage Ingredient NDA Submissiondate
RAPAFLO CAPSULE;ORAL silodosin 022206 2012-10-09

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength4MG
Approval Date:Oct 8, 2008TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength8MG
Approval Date:Oct 8, 2008TE:ABRLD:Yes

Expired US Patents for NDA 022206

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008   Start Trial   Start Trial
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008   Start Trial   Start Trial
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008   Start Trial   Start Trial
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008   Start Trial   Start Trial
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Medtronic
Express Scripts
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.